The American Society of Clinical Oncology guidelines include markers such as the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) as useful and non-invasive tests that can help determine the prognosis and further treatment, and markers such as CEA and CA15-3 in the monitoring of treatment in BC. This evidence concerns the gene ESR1 and breast cancer.